用于靶向胶质母细胞瘤的基因改造T细胞。
Genetically modified T cells to target glioblastoma.
作者信息
Krebs Simone, Rodríguez-Cruz Tania G, Derenzo Christopher, Gottschalk Stephen
机构信息
Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine , Houston, TX , USA ; Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine , Houston, TX , USA ; Department of Pediatrics, Baylor College of Medicine , Houston, TX , USA.
Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine , Houston, TX , USA ; Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine , Houston, TX , USA ; Department of Pediatrics, Baylor College of Medicine , Houston, TX , USA ; Department of Pathology and Immunology, Baylor College of Medicine , Houston, TX , USA.
出版信息
Front Oncol. 2013 Dec 31;3:322. doi: 10.3389/fonc.2013.00322.
Despite advances in surgical procedures, radiation, and chemotherapy the outcome for patients with glioblastoma (GBM) remains poor. While GBM cells express antigens that are potentially recognized by T cells, GBMs prevent the induction of GBM-specific immune responses by creating an immunosuppressive microenvironment. The advent of gene transfer has allowed the rapid generation of antigen-specific T cells as well as T cells with enhanced effector function. Here we review recent advances in the field of cell therapy with genetically modified T cells and how these advances might improve outcomes for patients with GBM in the future.
尽管在外科手术、放疗和化疗方面取得了进展，但胶质母细胞瘤（GBM）患者的预后仍然很差。虽然GBM细胞表达可被T细胞潜在识别的抗原，但GBM通过创造免疫抑制微环境来阻止GBM特异性免疫反应的诱导。基因转移技术的出现使得能够快速产生抗原特异性T细胞以及具有增强效应功能的T细胞。在此，我们综述了基因修饰T细胞在细胞治疗领域的最新进展，以及这些进展未来如何可能改善GBM患者的预后。
Zotero 插件